Liquidia (NASDAQ:LQDA) Issues Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Liquidia (NASDAQ:LQDA) announced its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08), Zacks reports. The business had revenue of $2.92 million during the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

Liquidia Stock Performance

NASDAQ:LQDA opened at $15.44 on Friday. Liquidia has a one year low of $8.26 and a one year high of $16.99. The stock has a market cap of $1.31 billion, a PE ratio of -9.47 and a beta of 0.07. The stock has a 50 day moving average price of $14.73 and a 200 day moving average price of $12.14.

Insider Buying and Selling at Liquidia

In related news, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the transaction, the general counsel now directly owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $275,298.60. Following the completion of the transaction, the chief financial officer now owns 401,755 shares of the company’s stock, valued at $4,732,673.90. The trade was a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock worth $843,326 in the last three months. 30.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LQDA. Scotiabank boosted their price objective on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Thursday. Needham & Company LLC upped their price objective on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).